The Cost of Cochlear Implantation: A Review of Methodological Considerations by Nadège, Costa et al.
Hindawi Publishing Corporation
International Journal of Otolaryngology
Volume 2011, Article ID 210838, 13 pages
doi:10.1155/2011/210838
Review Article
The Cost of Cochlear Implantation: A Review of
Methodological Considerations
Costa Nad` ege,1,2 GarnaultVal´ erie,1 FerlicoqLaura,1 Derumeaux-BurelH´ el` ene,1
BongardVanina,2,3 DeguineOlivier,4 FraysseBernard,4 andMolinierLaurent1,2
1Department of Medical Information, University Hospital, 31059 Toulouse Cedex 9, France
2UMR 1027, INSERM-University Paul Sabatier Toulouse III, 31073 Toulouse, France
3Department of Epidemiology, Health Economics and Public Health, University Hospital, 31073 Toulouse, France
4Department of Otolaryngology, University Hospital, 31059 Cedex 9 Toulouse, France
Correspondence should be addressed to Molinier Laurent, molinier.l@chu-toulouse.fr
Received 17 June 2011; Accepted 5 August 2011
Academic Editor: Ingeborg Dhooge
Copyright © 2011 Costa Nad` ege et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives. Cost studies can provide useful guidance, so long as they adhere to accepted methodology. Cochlear implants (CIs)
are electronic devices introduced surgically into the inner ear. It is a relevant example to review cost study analyses because of its
costliness. The aim of this study was to review relevant published cost studies of CI to analyze the method used. Methods. First,
we described the key points of cost study methodology. Cost studies relating to CI were systematically reviewed, focussing on
an analysis of the diﬀerent methods used. Results. The methods, data sources, and estimated cost categories in each study varied
widely. The paper showed that cost studies adopted signiﬁcantly diﬀerent approaches to estimate costs of CI, reﬂecting a lack of
consensus on the methodology of cost studies. Conclusion. To increase its credibility, closer agreement among researchers on the
methodological principles of cost studies would be desirable.
1.Introduction
Cochlear implants are electronic devices introduced surgi-
cally into the inner ear. These implants restore useful hearing
to profoundly or totally hearing-impaired patients. There is
no comparable alternative medical treatment for profound-
total deafness. Unlike hearing aids, cochlear implantation
(CI) necessitates a surgical procedure and incurs substantial
costs throughout the lifetime of the recipient. In actual
practice, the rehabilitation process has to be continued for
several years, especially in children [1].
CI has taken an important rise in many countries in the
last twenty years. Decision makers in charge of public health
are faced with the decision of whether to include cochlear
implants in the basic medical beneﬁt package. In the face
of scarce resources, decision makers are not only interested
in the eﬀectiveness of certain healthcare interventions but
also in the costs that are involved. Several studies have
analysed the costs of cochlear implants, in particular in the
United Kingdom [2–14], United States [15–22], Australia
[23], France [24], The Netherlands [25], Germany [26],
Belgium [27], and Asia [28, 29], and some of these studies
have shown the costs of CI for healthcare systems, leading to
major rethinking in the ﬁeld of health cost rationalization.
Healthcare ﬁnancing conditions are ﬁtted to these countries,
and diﬀerences in healthcare settings inﬂuence the results of
a cost analysis.
Cost study aims to describe the economic burden of a
speciﬁc disease to society. They are designed to evaluate not
only the costs attributable to the treatment of a particular
illness but also to evaluate actual illness-related global costs
[27]. In principle, they should either inform the most accu-
ratechoicesinresourceallocationorbeusedinfulleconomic
evaluations of healthcare programmes and treatments [30,
31]. Cost studies have been criticised for not really providing
useful information or enabling choice of priorities [32, 33].
It can however play an important role in informing cost
estimates for use in further economic evaluations [34, 35].
Thesestudiesshouldbecarriedoutinaccordancewithaclear
and widely accepted methodology [34, 36].2 International Journal of Otolaryngology
The aim of this study was to review relevant published
cost studies of cochlear implant to analyze the method used.
First, we provided a general description of the cost study
method.Wethensystematicallyreviewedthestudiesoncosts
relating to cochlear implantation, analyzing the diﬀerent
methods used.
2. Methods
2.1.CostStudy. Toconductacoststudy,itisnecessarytoﬁrst
deﬁne the pathological state, the epidemiological approach,
the type of costs to be assessed, and, thus, the perspective
of the study. Subsequently, data on resource consumption
and unit costs can be gathered, and results presented and
methodically discussed, in conjunction with sensitivity
analysis to test their robustness.
2.1.1.DeﬁningtheDiseaseandthePatient. Thecostsattribut-
able to an illness depend widely on how the disease is deﬁned
diagnostically. Studies habitually use the International Clas-
siﬁcation of Disease (ICD 10th). Cost study should precisely
deﬁne the disease stage investigated, including the identi-
ﬁcation of subgroups of patients according to clinical and
economicalcriteria.Thismakestheanalysismorepreciseand
relevant.
2.1.2. Perspective of the Analysis and Costs Assessed. Diﬀerent
types of costs (direct, indirect, and intangible) are included
in economic evaluations, depending on the study’s point of
view. For example, when the healthcare system perspective
is taken, only direct healthcare costs incurred by the payer
(National Health Insurance) are considered. Instead, when a
societal point of view is taken, indirect costs and the “out-of-
pocket” for patient and family must also be included.
2.1.3. Estimating Resource Consumption. Methods for esti-
mating resource consumption vary depending on the avail-
ability of the data.
A cost study can be prospectively or retrospectively
performed depending on the temporal relationship between
the initiation of the study and the data collection.
In prospective cost studies, the relevant events have not
already occurred when the study is initiated. The process of
data collection needs to be done by followingup a sample of
patients over the study period. This approach usually uses
medical records, data collected during clinical trials, and
questionnaires to patients.
Conversely, in retrospective cost study, all the relevant
events have already occurred when the study is initiated. The
processofdatacollectionmustrefertodataalreadyrecorded.
Forthisapproach,theactivitydatacanbecollectedeither
using aggregate ﬁgures from hospital admissions, consulta-
tions, mortality, and so forth, (“top-down” method), or by
referring to the record of a sample of patients (“bottom-up”
method).
A prospective approach (e.g., from medical records or
clinical trials) is preferred to a retrospective approach be-
cause of the bias risk and the quality data [37].
2.1.4. Valuation of Unit Costs. Costs should represent the
value of the input in its best alternative use, that is, the
opportunity cost. In a well-functioning, competitive market,
this would be the minimum price required to use the input
in its current use rather than in an alternative use [31, 38].
Direct costs measure the resources used to treat an
illness. It can be estimated in many ways depending on the
studydesign.Thesemethodsincludepercapitaexpenditures,
national tariﬀs, market prices, data from published studies,
and speciﬁc estimates. Patient’s charges and tariﬀsd on o t
generally give an accurate estimate of the underlying costs.
M a r k e tp r i c ec a nb eu s e dt ov a l u es o m ec o s t sc a t e g o r i e s
like drugs and rehabilitation items (e.g., eyeglasses, hearing
aids, etc.). Data published in studies conducted in other
countries are biased to the healthcare system considered, and
to local medical practice in the country where the study
was conducted. Therefore, the results are unlikely to be
transferable from one setting to another. The use of costs
estimated by some healthcare centres or hospitals, based on
an accounting principle, is another way to value direct costs.
However, since many costs may be hard to attribute directly
to speciﬁc items (e.g., overhead), methodology should be
clearly speciﬁed.
Medical care costs are characterized by certain distri-
butional properties (e.g., analytical accounting). Failure to
account for these issues will result in a biased estimate of
costsandmisguidedconclusionsofthestudy.Censoringdata
is recognised as an issue that can bias cost studies.
Indirect costs measure lost productivity, that is, the eﬀect
of the illness on the ability of either patients or their care-
givers to work (e.g., lost income) or engage in other activity
(e.g., cleaning the house). Two methods are usually used
to value indirect costs. The human capital approach (HCA)
is mainly used and based on the principle of productive
potential [39, 40]. This method measures the lost produc-
tion, in terms of lost earnings, of a patient or caregiver and
often includes the value of household work, usually valued
as the opportunity cost of hiring a replacement from the
labour market. Friction cost method (FCM) assumes that,
in the absence of full employment, indirect costs occur
only during the time necessary to restore the initial level
of production (e.g., friction period) by replacing the sick
worker or by reorganizing the production process [30, 31].
When production losses because of mortality are not
considered, future lost earnings are neglected [40, 41].
Productivity costs estimated by the HCA were more than
three times higher than the productivity costs estimated by
the FMC [42]. HCA overestimates the magnitude of indirect
costs. But FMC is seldom applied as it requires a huge
amount of information.
Educational costs in implanted children measure the
placement costs in an educational setting and the support
costs provided by language pathologists, educational audi-
ologists, special educators, teachers of the hearing impaired,
interpreters, occupational therapists, and instructional assis-
tants [17]. Cost of placement in an educational setting is
often assessed through public education budge, and support
costs are valued through salary costs of public and special
school [3, 17, 19, 26].International Journal of Otolaryngology 3
2.1.5. Discounting Costs. Discounting is an economic
method that captures an individual’s preference for income
today rather than income in the future and is frequently
applied when cost studies are considered over several years.
In the UK, the choice of a discount rate originates from the
socialopportunitycostapproach,butithasincreasinglybeen
viewed as an interest psychological rate of the society [31].
In the USA, the public health service panel on cost
eﬀectiveness in health and medicine estimates that the most
appropriate discount rate is 3% [43].
The following equation is applied to estimate costs:
Ca = Ct
t 
n=1
(1+r)
−n,( 1 )
where Ca present value of cost strategy, Ct is value of cost
strategy in year t, r is discount rate, and t is time period.
2.1.6. Sensitivity Analysis. A sensitivity analysis is recom-
mended in cost studies that contain a certain degree of un-
certainty. This type of analysis tests the robustness of the
results by varying in a range of key variables (e.g., pre-
valence or incidence rate, discounting rate, unit costs,
survival probabilities, etc.). A sensitivity analysis can take
various forms: simple, multiway, and probabilistic [44]. For
cost studies, it seems particularly interesting to do sensitivity
analysis using diﬀerent methods for estimating types of cost.
Also, it seems more credible for health policy analysis to
present the cost studies as a range of possible costs.
2.1.7. Presentation of Results. The presentation of cost study
results should be consistent with collected data and should
breakdownresultsintoasmanycomponentsaspossiblewith
full explanation given for clarity.
2.2. Literature Review
2.2.1. Study Selection. A bibliographic search was performed
on an international medical literature database (Med-
line, from 1966 until April 2011). All studies published
in English that assessed costs of CI were selected. Five
combinations using keywords were carried out (“cochlear
implant” AND “cost study” OR “cochlear implant” AND
“costanalysis”OR“cochlearimplant”AND“costevaluation”
OR “cochlear implant” AND “economic evaluation” OR
“cochlear implant” AND “economic analysis”). The results
of this search provided us with 157 studies, 136 of which
were in English language. On these 136, 94 studies did not
deal with costs of cochlear implantation and 3 studies were
duplicated. Forty two abstracts were ﬁrstly selected, 37 of
them underwent a subsequent full paper reading, thus pro-
viding 26 papers. Figure 1 illustrates the literature search and
selection process and presents reasons for excluded studies.
Our aim was to assess the methods adopted by the
authors rather than to compare cost estimates.
2.2.2. Study Review. A systematic review was performed.
One author (N. Costa) selected abstracts. Five method-
ologists (N. Costa, H. Derumeaux-Burel, L. Ferlicoq, V.
Garnault, and L. Molinier) each read the 37 papers retrieved
by the search strategy and reviewed the 26 selected papers. L.
Molinier did not participated in the analysis to the study he
previously published “The economics of cochlear implant
management in France: a multicentre analysis” [24]. In
keeping with the key methodological points identiﬁed in the
ﬁrst part of the paper, they asked questions based on existing
checklists for full economic evaluations [32, 45]. An equal
weight was given to each item. The ﬁnal score was the sum
of the 13 individual items. The objective was not to establish
a hierarchy in the criteria used by allocating them diﬀerent
weights,buttousethesecriteriatoanalysethemethodsused.
Each study was assessed separately by the reviewers. Finally,
a meeting to review the outcome was called, and a consensus
was reached by discussion. For each item, an agreement
between the reviewers was found. Then, all authors, both
clinicians and methodologists, discussed the results.
3. Results
Twenty six studies met our criteria (Table 1). Sixteen studies
were carried out in Europe [2–7, 9, 10, 12–14, 24–27], 7 in
North America [7, 15–17, 19, 20, 22], 2 in Asia [28, 29], and
1i nA u s t r a l i a[ 23].
Eight studies were cost analysis studies [2–4, 9, 19, 24,
25, 27], and 18 were global economic evaluations, including
16 cost-utility analyses [5–8, 10, 12–16, 20–23, 28, 29]a n d2
costs-beneﬁt analysis [17, 26].
Nineteen studies selected a sample ranging in size from 8
to 403 patients [2–5, 9, 12–17, 19–25, 27, 28]. Three studies
modelled costs without including patients [6, 7, 13].
3.1. Deﬁning the Disease and Population. Cochlear implants
are devices that are indicated to treat severe to profound
deafness.Implantationcanbedoneunilaterally(i.e.,oneear)
or bilaterally (i.e., both ears). The indications of CI depend
widely on deafness severity and children or adults recipients.
Seven studies were performed on adults [12, 14, 20–
22, 27, 28]. Among these, 5 deﬁned the deafness as profound
[12, 14, 21, 22, 27], one as severe to profound [20], and
one did not specify the severity of the deafness. Three
studies indicated the nature of implantation, bilateral for
Vantrappen et al. [27], unilateral for the UK CISG [14], and
both for Summerﬁeld et al. [12]. No studies have used the
ICD 10th for deﬁning the disease. This classiﬁcation lacks of
precision for deﬁning hearing loss and the indications of CI.
Thirteen studies were performed on children [2–5, 7–9,
13, 16, 17, 19, 25, 26]. Five deﬁned the deafness as profound
[8, 9, 16, 17, 19], one as severe [26], one as moderate [4],
and six studies did not specify the level of deafness [2, 3, 5,
7, 13, 25]. Two studies indicated the nature of implantation,
unilateral for Barton et al. [2] and unilateral and bilateral for
Summerﬁeld et al. [13].
Six studies included an assessment of cochlear implanta-
tion costs in both adults and children [6, 10, 15, 23, 24, 29].
Three deﬁned the deafness as severe to profound [6, 15, 24],
one as partial or profound [23], one as profound [10],
and one did not specify the level of deafness [29]. Bond4 International Journal of Otolaryngology
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Figure 1: Literature search and selection process.
et al. indicated the unilaterally and bilaterally nature of
implantation [6].
3.2. Perspective of the Analysis and Costs Assessed. Six studies
did not specify the viewpoint adopted [3, 7, 17, 19, 21,
22]. Ten studies, including 8 European studies, adopted the
healthcare payer’s perspective [2, 6, 8, 12–14, 20, 23, 24, 26].
The service provider perspective was used in 5 studies [10,
15, 27–29] and the family perspective in 2 studies [4, 9]. The
costs analysis was performed from the societal point of view
in 3 studies [5, 16, 25].
Thirteen studies quantiﬁed only the direct medical costs
[2, 9, 10, 12, 13, 15, 20–23, 26, 27, 29]. Direct costs con-
sidered by most studies included preoperative assessment,
surgery, implant device, and followup (maintenance and
rehabilitation).
Two studies quantiﬁed both direct medical and nonmed-
ical costs, limited to travel costs [24, 25]. Molinier et al. [24]International Journal of Otolaryngology 5
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estimated that travel costs accounted for 7% of total direct
costs over one year. Severens et al. [25] have not broken up
direct nonmedical costs per year.
Six studies [6–8, 17, 19, 26] estimated direct costs and
educational costs. Four studies assessed education costs with
a time horizon of one year [7, 8, 16, 19], while Schulze-
Gattermann et al. assessed these costs during the school
lifetime.
Four studies evaluated both direct and indirect costs
[4, 5, 9, 16]. Cheng et al. [16] estimated travel costs and
education costs as indirect costs. All of these estimated
indirect costs in terms of loss productivity.
Barton et al. [3] only estimated the education costs.
3.3. Estimating Resource Consumption. Thirteen studies esti-
mated resource consumption retrospectively [2–5, 9, 12, 14–
17, 26–28].
Nine studies used a bottom up approach to gather activ-
ity data [2–4, 9, 15–17, 26, 27]. In the German study [26],
dataonresourceutilisationwerecollectedfrompatientques-
tionnaire and four existing databases. The clinical records
of 16 patients were analyzed in the study of Bichey et al.
[15]. Two studies analyzed all procedures of each patient
in one and twelve hospitals, respectively, through hospital
database [2, 27]. Barton et al. [2] used also the clinical case
notes of each patient. All claims submitted to Medicare were
analyzed for 78 patients in the study of Cheng et al. [16].
Barton et al. have recorded educational data from teacher’s
questionnaires of 368 children [3], and they recorded the
amount of out-of-pocket, lost productivity, and transfer
payment (government beneﬁt) from parent’s questionnaires
of 468 children [4]. To estimate educational data of 27
children, Francis et al. [17] used parents’ interviews, school
consultation, and individualized education plan. Parents of
216 children were interviewed with semistructured face-to-
face interview in one American study [9] ,i no r d e rt or e c o r d
travel time and mode, lost productivity, and leisure time.
Four studies used a top-down approach [5, 12, 14,
28]. Resource consumption was estimated using mainly
published national indicators, data from national survey,
published study, and by expert advice. The use of top-
down approaches to assess resources consumption implies
aggregate data processing, which, if not properly performed,
could induce errors and unrealistic results. It was not always
o b v i o u st od e t e r m i n eh o wd a t ao nr e s o u r c ec o n s u m p t i o n
were processed to obtain more detailed data. To estimate
resource utilisation, Barton et al. [5] used published sources,
and Lee et al. [28] used hospital data and provided estimates
based on the references by two otology physicians. Two
studies [12, 14] have chosen to create a common proﬁle of
patient care and to combine it with the date of implantation
of each patient.
Four studies estimated resource consumption prospec-
tively [10, 20, 24, 25]. Molinier et al. [24]r e c o r d e dd a t a
through patient questionnaire for 306 children and 254
adults and Palmer et al. [20] through a diary for 40 adults. In
two studies [10, 25], time spent on various activities related
to implantation was collected by the several professionals
involved in cochlear implantation.
Six studies [6, 7, 13, 21–23] used decision model and
estimated resource consumption mainly through published
sources.
Two studies did not precise the approach used to gather
activity data [8, 19]. One study [8] used published national
sources, and another one [19] used questionnaire and pub-
lished national sources to estimate resource consumption.
The studies collected information over various periods.
The follow-up period was the lifetime period (i.e., time to
implantation until death) in 13 studies. Five of these studies
included only children [2, 5, 7, 8, 16], ﬁve included only
adults [12, 14, 20–22], and 3 included both children and
adults [6, 13, 29]. Lifetime period ranged from 71 to 73 years
for children and ranged from 21 to 33 years for adults. The
one-yearfollow-upperiod wasconsideredin5studies. Three
of these studies included only children [4, 9, 19], and one
included adults [3, 17, 26]. This period ranged from 12 to 15
years. Three studies chose a followup of 5 years for children
[25], 12 years, and 20 years, respectively, for both adults and
children [10, 23]. Three studies did not specify the follow-up
period [15, 28].
3.4. Valuation of Unit Costs. Diﬀerent methods, mainly
extrapolations from national sources and published data,
were adopted to assess direct costs. One American study
estimated costs mainly from Medicare payments and from
wholesale prices for implant device [16]. A German study
[26] valued direct medical costs from answers resulting
from the parents’ questionnaire and from the Medical
University of Hanover accounting database. A French study
[24] assessed hospital costs with the French DRGs and the
national unit cost scale, implant device with retail prices, and
other costs with the appropriate reimbursement tariﬀs used
by French Social Health Insurance. No information relating
to the valuation of unit costs was reported in the Chinese
study [29] .T h r e es t u d i e s[ 12, 15, 22] took into account costs
calculated in hospitals. Summerﬁel et al. [12] used also retail
pricesforimplantdevice.Leeetal.[28]usednormativecosts,
which two otology physicians estimated based on references
and hospital data. Palmer et al. [20]r e c o r d e da c t u a lc h a r g e s
on one hospital and physician bills that were obtained from
study participants. When bills were not available, they used
the price based on the 1996 Medicare maximum allowable
charge and the Red Book wholesale drug price. Francis
et al. [17] estimated direct costs based on 1997 cost data
from The Listening Center. The method of microcosting,
in which a unit cost is derived for each resource, was used
in two studies [2, 27]. Vantrappen et al. [27] used also the
reimbursement of CI device by social health insurance. In
The Netherlands study [25], cost was estimated through
price of hospital day in one center, retail prices for implant
device, and reimbursement prices for diagnostic tests. Price
of hospital day was obtained by dividing the total annual
cost by the actual number of hospitalization days in the
Ear, Nose and Throat Department. An English study [14]
determined costs with the UK NHS data. Two studies [4, 9]
assessed direct non medical costs incurred by families as out-
of-pocket expenditure and travel costs by using the value
estimated by respondents.8 International Journal of Otolaryngology
Several studies have quantiﬁed educational costs. Cost
data for two American studies [17, 19] were derived from
the State of Maryland Department of Education Budget and
from the salary costs of public schools without overhead.
The German study [26] used public authorities’ charges to
estimate educational costs. Barton et al. [3] assessed educa-
tional costs through a UK government report (Department
for Education and Skills, 2002) for nursery, primary, and
secondary schools, and a UK School inspection reports for
special schools and schools for deaf children. They valued
support costs through the budgets that special education UK
services devote to children with impaired hearing.
Four studies quantiﬁed indirect costs [4, 5, 9, 16]. Three
studies have valued lost of parents productivity with the
HCA. Cheng et al. [16] used the parents’ wage until their
children would be aged 18 years. Two other studies [4, 9]
used an average gross weekly wage rate, derived from the
New Earning Survey 2002, minus 35% to take account of tax,
pension, and national insurance. These two studies took into
account leisure time, but they did not value this time. One
study quantiﬁed change in future earning for children [16],
by taking into account diﬀerences in school placement and
nondeaf and deaf employment rates and wages. Sach et al.
valued children’s missed schooling using published estimate
of lifetime earnings per hour of special education [9].
3.5. Discounting Costs. Costs were discounted in 22 studies.
The discount rate chosen was 6% for 7 studies [2, 7, 8, 10,
12, 14, 26], 5% for six studies [17, 20–23, 25], 3, 5% for two
studies [6, 13], and 3% for four studies [3–5, 28]. One study
discountedcostswithtwodiscountrates,3and5%[16].One
study did not specify the rate value.
In two studies where costs were not discounted, the time
horizon was short (=1y e a ri nb o t hs t u d i e s )[ 9, 24].
3.6. Sensitivity Analysis. Fifteen studies [3, 4, 6, 8, 9, 13,
14, 16, 20–23, 26, 28] performed a sensitivity analysis and
discussed the variables that had a signiﬁcant impact on cost
estimates. Many key variables were identiﬁed. Two variables
were particularly analyzed in these studies. Nine studies [2,
6, 8, 12, 14, 21–23, 28] analyzed the discount rate variation,
and six [6, 8, 14, 20–22] analyzed the variation of the period
during which cochlear implant was used. Two studies [7, 17]
performed a sensitivity analysis without deﬁning the key
variables.
3.7. Presentation of Results. Most studies presented results
clearly. They were mainly well explained and consistently
set out in relation to the methods adopted. Nevertheless,
one study [29] presented results without deﬁning the cost
analysis method. Eight studies [5, 15–17, 19, 26, 28, 29] did
not suﬃciently disaggregate costs, thus reducing the strength
of the information provided.
All studies presented results in terms of cost per patient.
One English study [3] proposed also the total health-service
costs of implanting new children and providing followup to
children already implanted.
According to the key methodological points, we have
drafted a checklist of questions related to the seven items
analyzed (Table 2). For 12 studies [2–4, 6, 12–14, 16, 23–
26, 35], the answer of seven to ten questions was “yes.”
This checklist was developed on the model described by
Drummond et al. [31] and adapted to the cost studies by
Molinier et al. [46].
4. Discussion
This study reviews 26 cost studies on cochlear implantation
with the main goal of analyzing the various methodologies.
According to the key methodological points, three studies
were scored “yes” on the majority of the questions [2, 3, 12,
13, 16, 23–26]. Three studies scored “yes” to any questions
[4, 6, 14].
Studiesanalyzedhereconﬁrmthatcochlearimplantation
is costly the ﬁrst year after implantation.
Nevertheless,commentingonthesequantitativeresultsis
problematic because signiﬁcantly diﬀerent approaches have
been adopted to estimate the costs of cochlear implantation.
Thereisalsomarkeddiﬀerencesinthetypesofcostsincluded
and the sources used to assess activity data. Therefore, the
comparison of the results reported in each study is not
very useful. The methods used to estimate CI costs vary
widely across studies in the literature, which is probably due
to the lack of consensus on the methodology. Therefore,
the deﬁnition of standards, with a large consensus in the
methodology selected to conduct these studies, should be a
major concern for the scientiﬁc community [47, 48]. Bloom
et al. propose in a ﬁrst step to implement guidelines to
standardized methods and study design for cost studies [49].
Nevertheless, we must bear in mind that, unlike clinical
trial results, it is very diﬃcult to generalize quantitative
results of economic studies conducted in diﬀerent countries.
Economic results are diﬃcult to compare on account of
monetary issues, such as ﬂuctuating exchange rates and
diﬀerent purchasing powers of currencies. Domestic charac-
teristics also dramatically aﬀect resource consumption and
unit costs, including diﬀerences in clinical practice and
healthcare system framework.
As several studies did not fully explain their methods,
they were diﬃcult to assess. This might be due to a general
lack of economic awareness in the medical journals that
support economic studies. Most of the studies reviewed
were published in journals that did not demand suﬃciently
detailed and explicit explanations about the methodologies
chosen. In 1996, the British Medical Journal published
guidance information to authors and peer reviewers on
economic evaluation, but it did not address costs studies
[50]. A detailed description of the methodological choices
would improve the credibility of cost studies.
5. Conclusion
Cost studies can provide information to support the political
process as well as the management functions at diﬀerent
levels of healthcare organizations. These studies must be ableInternational Journal of Otolaryngology 9
T
a
b
l
e
2
:
A
n
s
w
e
r
s
t
o
t
h
e
m
e
t
h
o
d
o
l
o
g
i
c
a
l
q
u
e
s
t
i
o
n
s
b
y
s
t
u
d
y
.
Q
u
e
s
t
i
o
n
/
a
n
s
w
e
r
s
W
a
s
a
c
l
e
a
r
d
e
ﬁ
n
i
t
i
o
n
o
f
t
h
e
d
e
a
f
n
e
s
s
g
i
v
e
n
?
W
e
r
e
t
h
e
m
e
t
h
o
d
s
a
d
o
p
t
e
d
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
s
o
u
r
c
e
s
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
a
p
p
r
o
p
r
i
a
t
e
l
y
a
s
s
e
s
s
e
d
?
W
e
r
e
t
h
e
s
o
u
r
c
e
s
o
f
a
l
l
c
o
s
t
v
a
l
u
e
s
a
n
a
l
y
t
i
c
a
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
u
n
i
t
c
o
s
t
s
a
p
p
r
o
p
r
i
-
a
t
e
l
y
v
a
l
u
e
d
?
W
e
r
e
c
o
s
t
s
s
u
ﬃ
c
i
e
n
t
l
y
d
i
s
a
g
g
r
e
g
a
t
e
d
?
W
e
r
e
t
h
e
m
a
j
o
r
a
s
s
u
m
p
t
i
o
n
s
t
e
s
t
e
d
i
n
a
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
?
W
e
r
e
c
o
s
t
s
d
i
s
c
o
u
n
t
e
d
?
W
a
s
t
h
e
p
r
e
s
e
n
t
a
t
i
o
n
o
f
s
t
u
d
y
r
e
s
u
l
t
s
c
o
n
s
i
s
t
e
n
t
w
i
t
h
t
h
e
m
e
t
h
o
l
o
g
y
o
f
t
h
e
s
t
u
d
y
?
T
o
t
a
l
s
c
o
r
e
b
y
s
t
u
d
y
Y
1
0
1
7
1
9
1
0
1
9
1
4
1
0
1
6
2
1
1
6
1
5
4
A
l
l
s
t
u
d
i
e
s
P
1
2
7
3
7
1
6
1
0
2
1
7
5
6
N
4
2
4
9
6
6
6
8
4
3
5
3
Y
Y
e
s
Y
e
s
4
O
’
N
e
i
l
l
e
t
a
l
.
[
8
]
P
P
P
P
3
N
N
o
N
o
N
o
N
o
N
o
5
S
u
m
m
e
r
ﬁ
e
l
d
e
t
a
l
.
[
1
2
]
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
8
P
P
P
2
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
7
B
a
r
t
o
n
e
t
a
l
.
[
2
]
P
P
P
P
3
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
9
S
e
v
e
r
e
n
s
e
t
a
l
.
[
2
5
]
P
0
N
N
o
1
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
5
P
a
l
m
e
r
e
t
a
l
.
[
2
0
]
P
P
P
P
P
P
5
N
0
Y
Y
e
s
Y
e
s
2
H
u
t
t
o
n
e
t
a
l
.
[
7
]
P
P
P
P
3
N
N
o
N
o
N
o
N
o
N
o
5
S
c
h
u
l
z
e
-
G
a
t
t
e
r
m
a
n
n
e
t
a
l
.
[
2
6
]
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
8
P
P
P
2
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
7
C
h
e
n
g
e
t
a
l
.
[
1
6
]
P
P
P
P
3
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
5
W
y
a
t
t
e
t
a
l
.
[
2
1
]
P
P
P
P
3
N
N
o
N
o
2
Y
Y
e
s
Y
e
s
2
L
e
e
e
t
a
l
.
[
2
8
]
P
P
P
P
3
N
N
o
N
o
N
o
N
o
N
o
510 International Journal of Otolaryngology
T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
Q
u
e
s
t
i
o
n
/
a
n
s
w
e
r
s
W
a
s
a
c
l
e
a
r
d
e
ﬁ
n
i
t
i
o
n
o
f
t
h
e
d
e
a
f
n
e
s
s
g
i
v
e
n
?
W
e
r
e
t
h
e
m
e
t
h
o
d
s
a
d
o
p
t
e
d
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
s
o
u
r
c
e
s
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
a
p
p
r
o
p
r
i
a
t
e
l
y
a
s
s
e
s
s
e
d
?
W
e
r
e
t
h
e
s
o
u
r
c
e
s
o
f
a
l
l
c
o
s
t
v
a
l
u
e
s
a
n
a
l
y
t
i
c
a
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
u
n
i
t
c
o
s
t
s
a
p
p
r
o
p
r
i
-
a
t
e
l
y
v
a
l
u
e
d
?
W
e
r
e
c
o
s
t
s
s
u
ﬃ
c
i
e
n
t
l
y
d
i
s
a
g
g
r
e
g
a
t
e
d
?
W
e
r
e
t
h
e
m
a
j
o
r
a
s
s
u
m
p
t
i
o
n
s
t
e
s
t
e
d
i
n
a
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
?
W
e
r
e
c
o
s
t
s
d
i
s
c
o
u
n
t
e
d
?
W
a
s
t
h
e
p
r
e
s
e
n
t
a
t
i
o
n
o
f
s
t
u
d
y
r
e
s
u
l
t
s
c
o
n
s
i
s
t
e
n
t
w
i
t
h
t
h
e
m
e
t
h
o
l
o
g
y
o
f
t
h
e
s
t
u
d
y
?
T
o
t
a
l
s
c
o
r
e
b
y
s
t
u
d
y
S
u
m
m
e
r
ﬁ
e
l
d
e
t
a
l
.
[
1
3
]
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
7
P
P
P
P
3
N
0
V
a
n
t
r
a
p
p
e
n
e
t
a
l
.
[
2
7
]
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
6
P
P
P
2
N
N
o
N
o
2
Y
Y
e
s
1
W
o
n
g
e
t
a
l
.
[
2
9
]
P
0
N
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
9
Y
Y
e
s
Y
e
s
2
B
i
c
h
e
y
e
t
a
l
.
[
1
5
]
P
P
P
P
3
N
N
o
N
o
N
o
N
o
N
o
5
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
6
W
y
a
t
t
e
t
a
l
.
[
2
2
]
P
P
P
P
3
N
N
o
1
S
u
m
m
e
r
ﬁ
e
l
d
e
t
a
l
.
[
1
0
]
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
6
P
P
P
2
N
N
o
N
o
2
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
6
F
r
a
n
c
i
s
e
t
a
l
.
[
1
7
]
P
P
P
P
3
N
N
o
1
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
8
C
a
r
t
e
r
a
n
d
H
a
i
l
e
y
[
2
3
]
P
P
P
2
N
0International Journal of Otolaryngology 11
T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
Q
u
e
s
t
i
o
n
/
a
n
s
w
e
r
s
W
a
s
a
c
l
e
a
r
d
e
ﬁ
n
i
t
i
o
n
o
f
t
h
e
d
e
a
f
n
e
s
s
g
i
v
e
n
?
W
e
r
e
t
h
e
m
e
t
h
o
d
s
a
d
o
p
t
e
d
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
s
o
u
r
c
e
s
c
a
r
e
f
u
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
a
c
t
i
v
i
t
y
d
a
t
a
a
p
p
r
o
p
r
i
a
t
e
l
y
a
s
s
e
s
s
e
d
?
W
e
r
e
t
h
e
s
o
u
r
c
e
s
o
f
a
l
l
c
o
s
t
v
a
l
u
e
s
a
n
a
l
y
t
i
c
a
l
l
y
d
e
s
c
r
i
b
e
d
?
W
e
r
e
u
n
i
t
c
o
s
t
s
a
p
p
r
o
p
r
i
-
a
t
e
l
y
v
a
l
u
e
d
?
W
e
r
e
c
o
s
t
s
s
u
ﬃ
c
i
e
n
t
l
y
d
i
s
a
g
g
r
e
g
a
t
e
d
?
W
e
r
e
t
h
e
m
a
j
o
r
a
s
s
u
m
p
t
i
o
n
s
t
e
s
t
e
d
i
n
a
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
?
W
e
r
e
c
o
s
t
s
d
i
s
c
o
u
n
t
e
d
?
W
a
s
t
h
e
p
r
e
s
e
n
t
a
t
i
o
n
o
f
s
t
u
d
y
r
e
s
u
l
t
s
c
o
n
s
i
s
t
e
n
t
w
i
t
h
t
h
e
m
e
t
h
o
l
o
g
y
o
f
t
h
e
s
t
u
d
y
?
T
o
t
a
l
s
c
o
r
e
b
y
s
t
u
d
y
Y
Y
e
s
1
K
o
c
h
e
t
a
l
.
[
1
9
]
P
P
P
P
P
0
N
N
o
N
o
N
o
N
o
N
o
5
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
1
0
B
a
r
t
o
n
e
t
a
l
.
[
4
]
P
0
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
7
M
o
l
i
n
i
e
r
e
t
a
l
.
[
2
4
]
P
P
1
N
N
o
N
o
2
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
5
S
a
c
h
e
t
a
l
.
[
9
]
P
P
P
2
N
N
o
N
o
N
o
3
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
4
B
a
r
t
o
n
e
t
a
l
.
[
5
]
P
P
P
2
N
N
o
N
o
N
o
N
o
4
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
8
B
a
r
t
o
n
e
t
a
l
.
[
3
]
P
P
P
0
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
1
0
U
K
C
I
S
G
[
1
4
]
P
0
N
0
Y
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
1
0
B
o
n
d
e
t
a
l
.
[
6
]
P
0
N
0
T
o
t
a
l
s
c
o
r
e
b
y
s
t
u
d
y
i
s
t
h
e
s
u
m
o
f
a
n
s
w
e
r
s
.
P
:
p
a
r
t
i
a
l
l
y
;
Y
:
Y
e
s
;
N
:
N
o
.12 International Journal of Otolaryngology
to identify the actual clinical management of illness and to
measure true costs.
Cost study results can serve as a baseline for further eco-
nomic evaluations. Nevertheless, an insuﬃcient description
of methods may lead to misunderstandings. The cost studies
of CI identiﬁed in this paper highlight the poor consensus
of methodological approaches, perhaps reﬂecting a lack of
stringency on the part of medical journals. Hence, journal
should encourage researchers to give clear descriptions and
discuss limitations, and a further eﬀort should be made to
validate methodology.
The viewpoint of the analysis must be stated. Resource
consumption could be better estimated by the followup of a
sample of patients, and unit costs of the facilities provided
for patients’ care could be carefully assessed.
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